Deutsche Bank Ag\ Anavex Life Sciences Corp. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 39,520 shares of AVXL stock, worth $478,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares

39,520

Previous 24,993 58.12%

Holding current value

$478,587

Previous $105,000 113.33%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$4.11 - $7.04 $59,705 - $102,270	14,527 Added 58.12%	39,520 $224,000
Q2 2024 Aug 14, 2024	SELL	$3.39 - $5.02 $43,330 - $64,165	-12,782 Reduced 33.84%	24,993 $105,000
Q1 2024 May 15, 2024	SELL	$4.55 - $6.75 $12,676 - $18,805	-2,786 Reduced 6.87%	37,775 $192,000
Q4 2023 Feb 14, 2024	BUY	$5.04 - $9.95 $13,517 - $26,685	2,682 Added 7.08%	40,561 $377,000
Q3 2023 Nov 09, 2023	BUY	$6.55 - $9.37 $21,091 - $30,171	3,220 Added 9.29%	37,879 $248,000
Q2 2023 Aug 14, 2023	SELL	$7.66 - $9.5 $120,009 - $148,836	-15,667 Reduced 31.13%	34,659 $281,000
Q1 2023 May 15, 2023	BUY	$8.32 - $11.75 $75,104 - $106,067	9,027 Added 21.86%	50,326 $431,000
Q4 2022 Feb 13, 2023	BUY	$7.65 - $14.43 $87,531 - $165,108	11,442 Added 38.32%	41,299 $382,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $1.07 Million - $1.54 Million	-119,940 Reduced 80.07%	29,857 $308,000
Q2 2022 Aug 11, 2022	SELL	$7.31 - $12.84 $33,640 - $59,089	-4,602 Reduced 2.98%	149,797 $1.5 Million
Q1 2022 May 13, 2022	SELL	$9.74 - $17.69 $32,307 - $58,677	-3,317 Reduced 2.1%	154,399 $1.9 Million
Q4 2021 Feb 11, 2022	BUY	$16.88 - $23.31 $49,542 - $68,414	2,935 Added 1.9%	157,716 $2.74 Million
Q3 2021 Nov 04, 2021	BUY	$16.82 - $25.75 $1,076 - $1,648	64 Added 0.04%	154,781 $2.78 Million
Q2 2021 Aug 11, 2021	BUY	$10.16 - $28.86 $1.17 Million - $3.32 Million	115,103 Added 290.56%	154,717 $3.54 Million
Q1 2021 May 13, 2021	SELL	$5.17 - $16.13 $170 - $532	-33 Reduced 0.08%	39,614 $592,000
Q4 2020 Feb 16, 2021	BUY	$4.01 - $7.58 $43,316 - $81,879	10,802 Added 37.45%	39,647 $214,000
Q3 2020 Nov 12, 2020	BUY	$3.8 - $5.0 $9,397 - $12,365	2,473 Added 9.38%	28,845 $131,000
Q2 2020 Aug 13, 2020	BUY	$2.62 - $5.2 $20,789 - $41,262	7,935 Added 43.04%	26,372 $130,000
Q1 2020 May 14, 2020	BUY	$2.38 - $5.81 $7,513 - $18,342	3,157 Added 20.66%	18,437 $58,000
Q4 2019 Feb 14, 2020	BUY	$2.31 - $3.14 $2,042 - $2,775	884 Added 6.14%	15,280 $38,000
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.9 $39,722 - $69,782	-17,893 Reduced 55.42%	14,396 $44,000
Q2 2019 Aug 14, 2019	BUY	$2.75 - $3.7 $88,794 - $119,469	32,289 New	32,289 $108,000
Q1 2019 May 15, 2019	SELL	$1.68 - $3.42 $30,423 - $61,932	-18,109 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.25 - $2.75 $22,636 - $49,799	18,109 New	18,109 $28,000
Q3 2018 Nov 14, 2018	SELL	$2.23 - $3.82 $209,693 - $359,206	-94,033 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.08 - $4.26 $86,681 - $177,531	41,674 Added 79.59%	94,033 $245,000
Q1 2018 Oct 18, 2019	BUY	$2.32 - $3.44 $21,545 - $31,947	9,287 Added 21.56%	52,359 $144,000
Q1 2018 May 15, 2018	SELL	$2.32 - $3.44 $92,556 - $137,238	-39,895 Reduced 48.09%	43,072 $118,000
Q4 2017 Feb 14, 2018	BUY	$3.12 - $4.94 $155,700 - $246,525	49,904 Added 150.94%	82,967 $266,000
Q3 2017 Nov 14, 2017	BUY	$3.42 - $4.87 $113,075 - $161,016	33,063	33,063 $135,000

Others Institutions Holding AVXL

# of Institutions

155

Shares Held

27.3M

Call Options Held

515K

Put Options Held

838K

View Full List

About ANAVEX LIFE SCIENCES CORP.

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $944M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

More about AVXL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account